Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback